Endovenous Treatment for Acute Massive Pulmonary Thromboembolism

Hiroyuki Tajima, MD, PhD,1 Tadashi Kaneshiro,1 Naoko Takenoshita,1 Taro Ichikawa, MD, PhD,2 Saiko Isshiki,2 Satoru Murata, MD, PhD,3 Shiro Onozawa, MD, PhD,4 and Ken Nakazawa, MD, PhD5

Treatment for venous thromboembolic conditions differs significantly depending on whether the condition is acute or chronic. Endovenous treatment is now available for treating the most severe cases of acute massive pulmonary thromboembolism, and the goal is rapid central clot removal to relieve life-threatening pulmonary circulation. Endovenous catheter interventions include catheter-directed thrombolysis and catheter-assisted thrombus removal. The latter is divided into aspiration thrombectomy, fragmentation, and rheolytic thrombectomy. Data from cohort studies indicate that the clinical outcome and safety after open surgical treatment and endovenous treatment may be comparable. This paper reviews the current approaches to endovenous treatment for acute massive pulmonary thromboembolism, and presents our study of hybrid treatment using a combination of local fibrinolysis, mechanical fragmentation, and clot aspiration.

Keywords: catheter-directed thrombolysis, catheter-assisted thrombus removal, fragmentation, aspiration

Introduction

Although the etiology and pathology of pulmonary thromboembolism (PTE) are yet to be completely determined, it is known that deep vein thrombosis (DVT) plays an important role in the development of PTE. Thus, PTE may be considered a complication of DVT, and these conditions are regarded as a single disease entity that is termed venous thromboembolism (VTE).1)

The diagnosis and treatment for PTE differ significantly depending on whether the condition is acute or chronic. The immediate mortality rate of acute PTE is approximately 10%. Among the survivors, a confirmatory diagnosis cannot be made in 70% of patients, and the mortality rate of this group may approach 30%.2) Death in patients with acute massive PTE is caused by sudden circulatory collapse as a consequence of obstructed pulmonary blood flow. Initial therapy must therefore be directed toward rapidly restoring pulmonary circulation.3) Conventional therapeutic options are anticoagulation therapy, systemic thrombolysis, and surgical thrombectomy. Recently, endovenous treatments, including catheter-directed thrombolysis (CDT) and catheter-assisted thrombus removal (CATR) have been introduced for this condition.4)

The aim of these procedures is to prevent death due to right-sided heart failure through prompt peripheral dispersal of the central thrombus, resulting in reduced pulmonary vascular resistance and increased pulmonary flow.5)

This review describes the principles, current techniques, results, and complications of endovenous treatment for managing patients with life-threatening PTE.

Indications

Endovenous catheter intervention is indicated for patients with acute massive PTE with unstable hemodynamics despite other appropriate treatment. The indications for this treatment are as follows:
1. Arterial hypotension (<90 mmHg systolic);
2. Circulatory collapse with need for cardiopulmonary resuscitation (shock index: heart rate/systolic blood pressure > 1);
3. Right ventricular afterload stress and/or pulmonary hypertension (mean pulmonary arterial pressure > 25 mmHg);
4. Angiographic findings: Miller score > 20/34 (Fig. 1)5) or
Cardiopulmonary arrest on arrival is also a current indication for this therapy, and such patients are occasionally rescued (Figs. 2 and 3).

Fig. 1 Miller score. The right and left main pulmonary arteries are considered to have nine and seven major branches, respectively, and an embolus in any of these branches gives a score of one point. Each lung is considered to have an upper, middle and lower zone, and in each of these three zones, the absence of pulmonary artery flow confers a score of three points, severely reduced flow gives two points, mildly reduced flow one point, and normal flow scores 0 points. The Miller score can thus range from 0 to 34.

Definition of Techniques
Endovenous catheter interventions include CDT and CATR. The latter is divided into aspiration thrombectomy, fragmentation, and rheolytic thrombectomy.

Catheter-directed thrombolysis (CDT)
CDT with intrapulmonary infusion of thrombolytic drugs aims to accelerate clot lysis and achieve rapid reperfusion of the pulmonary circulation. In 1988 Verstraete et al. published a prospective, randomized, multicenter comparative study of intravenous versus intrapulmonary treatment with 100 mg of recombinant human-tissue plasminogen activator (rt-PA) over seven hours, which showed that intrapulmonary infusion offered no significant benefit over intravenous administration.

Proposed intrapulmonary CDT regimens are as follows:

- Urokinase: An infusion of 250,000 IU/h mixed with 2,000 IU of heparin over 2 h, followed by an infusion of 100,000 IU/h of urokinase for 12–24 h.
rt-PA: A bolus of 10 mg followed by 20 mg/h over 2 h, or 100 mg over 7 h. Mutant human-tissue plasminogen activator (Mt-PA) is only available in Japan. These regimens are applied approximately 5–10 times.

Residual right-heart disturbance may play an important role in the prognosis of acute PTE. Overnight CDT with 10 mg of rt-PA and ultrasound-accelerated thrombolysis are receiving a lot of attention, because they show improvement of the sub-annular right/left-ventricular dimension ratio and no increase in bleeding complications.\(^7,8\) The ultrasound-accelerated thrombolysis device is not yet permitted in Japan.

**Catheter-assisted thrombus removal (CATR)**

Catheter interventions other than CDT therapy include aspiration thrombectomy, thrombus fragmentation, and rheolytic thrombectomy. These techniques are followed by thrombolytic therapy in most cases. It has been suggested that the clinical results of these techniques are comparable to those of surgical thrombectomy.\(^9\) Efficacy evaluation should be based on improvements of the hemodynamics and oxygenation, and not on the angiographic findings.\(^10\)

**Aspiration thrombectomy**

The Greenfield embolectomy device was first introduced for the aspiration of acute PTE, but it is no longer popular because of poor operability. Aspiration thrombectomy using guiding catheters with a large lumen has attracted attention because of its simplicity and excellent clinical results.\(^11\) By contrast, catheters designed to remove thrombi from the coronary arteries percutaneously are not useful in the treatment of acute PTE because of their low suction power.

**Thrombus fragmentation**

Thrombus fragmentation is performed to directly break the thrombotic mass in a proximal pulmonary artery and redistribute microemboli into the peripheral vessels\(^2\) (Fig. 5). Considering that the cross-sectional area of the distal arterioles is more than four times that of the central circulation, and that the volume of the peripheral circulatory bed is approximately twice that of the pulmonary arteries, the redistribution of large central clots as smaller clots in the peripheral pulmonary arteries may acutely improve cardiopulmonary hemodynamics, with significant increases in total pulmonary blood flow and right-ventricular function.\(^5\) Although the thrombi are not recovered, small fragments of a thrombotic mass respond better to thrombolytic therapy because the total surface area exposed to thrombolytics is increased significantly. Currently used methods of fragmentation include cutting a thrombotic mass by rotating a modified pigtail catheter\(^12\) and crushing the mass with a balloon catheter.

**Rheolytic thrombectomy**

Rheolytic thrombectomy is a theoretically safe method because the thrombi are removed, but it can be ineffective in many cases when used alone to treat acute PTE. Angio Jet (Boston Scientific, Marlborough MA, USA) is now withdrawn from the market because the US Food and Drug Administration has issued a black-box warning on the device label.\(^13\)

**Hybrid Treatment**

In very severe cases of PTE, the total volume of thromboemboli in the pulmonary vascular trees is extremely large,
and mono-therapy with thrombolysis, thrombectomy, and aspiration is not effective. We have developed a combined approach to thrombolysis using mechanical fragmentation, localized fibrinolysis and clot aspiration and have achieved good results3) (Fig. 6).

Procedures
A 6-Fr conventional curved pigtail catheter for pulmonary angiography was used in the fragmentation catheter system. A long guidewire was placed in the pulmonary artery (PA) at a peripheral site, and the proximal tip of the guidewire was inserted into the most proximal hole of the curved pigtail catheter (Fig. 7). The catheter was then inserted over the guidewire and through the 8-Fr PA sheath. The emboli were fragmented by mechanical action of the rotating pigtail catheter. The catheter was manually rotated around the axis of the stationary guidewire, and advanced or withdrawn over the guidewire as required. After fragmentation, all patients received an intrapulmonary injection of rt-PA (640×10^4 IU, equivalent to 12.8 mg over 64 min), followed by manual clot aspiration using a large-lumen guide catheter. Strong manual aspiration was performed by drawing back the plunger of a regular Luer-Lok 20-mL syringe while slowly withdrawing the catheter through the introducer sheath. During thrombolysis, all patients received heparin sodium (initial dose: 5,000 IU, maintenance dose: sufficient to maintain an activated partial thromboplastin time ratio of 2). After this treatment, additional systemic urokinase was infused on the intensive care unit to remove residual thrombi, depending on the patient’s condition. The original dosing regimen was 24–48×10^4 IU/day for three days.

Eid-Lidt et al. evaluated another type of hybrid treatment, combining clot fragmentation with a conventional pigtail catheter and aspiration with Aspirex (Straub Medical, Wangs, Switzerland),14) and reported promising results15) (Fig. 8).

Results
A meta-analysis of 594 patients from 35 studies revealed that the pooled clinical success rate of CDT was 86.5%, and the pooled risks of minor and major procedural complications were 7.9% (95% confidence interval [CI]:
5.0–11.3%) and 2.4% (95% CI: 1.9–4.3%), respectively. No randomized comparative studies on medical and surgical treatment have been reported. The long-term outcomes of surgical embolectomy are generally good with acceptable survival rates, but the late mortality rates associated with catheter intervention have not yet been reported. Data from cohort studies indicate that the clinical outcome and safety of open surgical treatment and endovenous treatment may be comparable. The initial results from a prospective multicenter registry evaluating the safety and effectiveness of CDT for acute massive and sub-massive PTE have recently been reported, but no consensus has been reached. Data of treatment outcomes for very severe cases requiring extracorporeal life support treated with catheter-based intervention are limited; we showed that the 30-day mortality rate was 30%.

**Complications**

Minor bleeding at the insertion site occurred in 29 of the 348 patients (8%) with and without thrombolytic agents, and major bleeding at the insertion site occurred in 8 of the 348 patients (2%). One patient experienced perforation of the right ventricle with the Greenfield catheter. In a systemic review and meta-analysis, among 594 patients, the pooled risk of minor and major procedural complications was 7.9%, and 2.4%, respectively. Major procedural complications, including groin hematomas (n = 11: requiring transfusion), non-cerebral hemorrhages (n = 5: sites unspecified, requiring transfusion), massive hemoptysis requiring transfusion (n = 2), renal failure requiring hemodialysis (n = 1), cardiac tamponade (n = 1), and death (n = 5) occurred in 25 patients: five procedure-related deaths were all associated with the Angio Jet device.

**Guidelines**

There is a subtle difference in evaluation among the Japanese Circulation Society (JCS), the American College of Chest Physicians (ACCP), and the European Society of Cardiology (ESC) (Fig. 9). In the guidelines of the JCS, CDT and catheter fragmentation/aspiration thrombectomy are evaluated as Class IIb. In the guidelines of ACCP 2016, in patients with acute PE associated with hypotension and who have (i) a high risk of bleeding, (ii) failed systemic thrombolysis, or (iii) shock that is likely to cause death before systemic thrombolysis can take effect, if appropriate expertise and resources are available, catheter-assisted thrombus removal is suggested rather than no such intervention (Grade 2C). In ACCP 2016, surgical embolectomy was not mentioned, whereas in the 2012 guidelines, in patients with acute PE associated with hypotension, surgical pulmonary embolectomy is suggested rather than no such intervention if they have (i) contraindications to thrombolysis, (ii) failed thrombolysis or catheter-assisted embolectomy, or (iii) shock that is likely to cause death before thrombolysis can take effect, provided surgical expertise and resources are available (Grade 2C). In the 2014 guidelines of ESC, in high-risk groups percutaneous catheter-directed treatment should be considered as an alternative to surgical pulmonary embolectomy for patients in whom full-dose systemic thrombolytic therapy is contraindicated, but surgical expertise and resources are available (Grade 2C).
Endovenous Treatment of Acute Massive PTE

Bolysis is contraindicated or has failed, whereas surgical embolectomy or percutaneous catheter-directed treatment may be considered in intermediate-high-risk patient if the anticipated risk of bleeding under thrombolytic treatment is high.20)

Summary

The management of patients with massive PTE requires a team approach, including referring physicians, surgeons, and interventional radiologists. This review stresses the improvement of hemodynamics immediately after hybrid intervention treatment for acute PTE. Expeditious use of the catheter technique for embolectomy or fragmentation immediately after angiography provides the patient with the best chance of surviving the initial impact of this life-threatening condition.

Grants

This work was supported in part by a Research Project Grant-in-Aid for Scientific Research (C) (Project number 16K10365), from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Disclosure Statement

All authors have no conflict of interest to disclose regarding the submitted manuscript.

Author Contributions

Study conception: HT, KN
Data collection: HT, TK, NT
Analysis: HT, TI, SI

References

1) Ando M, Fukuda I, Ito M, et al.; JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis. Circ J 2011; 75: 1258-81.
2) Uflacker R. Intervention therapy for pulmonary embolism. J Vasc Interv Radiol 2001; 12: 147-64.
3) Tajima H, Murata S, Kumazaki T, et al. Hybrid treatment of acute massive pulmonary thromboembolism: mechanical fragmentation with a modified rotating pigtail catheter, local fibrinolytic therapy, and clot aspiration, followed by systemic fibrinolytic therapy. AJR Am J Roentgenol 2004; 183: 589-95.
4) Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149: 315-52.
5) Tajima H, Murata S, Kumazaki T, et al. Recent advances in interventional radiology for acute massive pulmonary thromboembolism. J Nippon Med Sch 2005; 72: 74-84.
6) Verstraete M, Miller GA, Bounnameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77: 353-60.
7) Kuo WT. Endovascular therapy for acute pulmonary embolism. J Vasc Interv Radiol 2012; 23: 167-79.
8) Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129: 479-86.
9) Skaf E, Beemath A, Siddiqui T, et al. Catheter-tip embolectomy in the management of acute massive pulmonary embolism. Am J Cardiol 2007; 99: 415-20.
10) Kucher N. Catheter embolectomy for acute pulmonary embolism. Chest 2007; 132: 657-63.
11) Tajima H, Murata S, Kumazaki T, et al. Manual aspiration thrombectomy with a standard PTCA guiding catheter for treatment of acute massive pulmonary thromboembolism. Radiat Med 2004; 22: 168-72.
12) Schmitz-Rode T, Janssens U, Duda SH, et al. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol 2000; 36: 375-80.
13) Kuo WT, Banerjee A, Kim PS, et al. Pulmonary embolism response to fragmentation, embolectomy, and catheter thrombolysis (PERFECT). Initial results from a prospective multicenter registry. Chest 2015; 148: 667-73.
14) Eid-Lidt G, Gaspar J, Sandoval J, et al. Combined clot fragmentation and aspiration in patients with acute pulmonary embolism. Chest 2008; 134: 54-60.
15) Kucher N and Goldhaber SZ. Mechanical catheter intervention in massive pulmonary embolism: proof of concept. Chest 2008; 134: 2-4.
16) Kuo WT, Gould MK, Louie JD, et al. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 2009; 20: 1431-40.

17) Fukuda I, Taniguchi S, Fukui K, et al. Improved outcome of surgical pulmonary embolectomy by aggressive intervention for critically ill patients. Ann Thorac Surg 2011; 91: 728-32.

18) Liang NL, Chaer RA, Avgerinos ED. Correspondence. Catheter-directed interventions for acute pulmonary embolism. The jury is still out. Chest 2015; 148: e93.

19) Munakata R, Yamamoto T, Hosokawa Y, et al. Massive pulmonary embolism requiring extracorporeal life support treated with catheter-based interventions. Int Heart J 2012; 53: 370-4.

20) Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033-73.

21) Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141 Suppl: e419S-96S.